181 related articles for article (PubMed ID: 20063545)
1. The challenge of risk stratification in acute myeloid leukemia with normal karyotype.
Zaidi SZ; Owaidah T; Al Sharif F; Ahmed SY; Chaudhri N; Aljurf M
Hematol Oncol Stem Cell Ther; 2008; 1(3):141-58. PubMed ID: 20063545
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Marcucci G; Mrózek K; Bloomfield CD
Curr Opin Hematol; 2005 Jan; 12(1):68-75. PubMed ID: 15604894
[TBL] [Abstract][Full Text] [Related]
3. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
6. [Molecular and cytogenetic prognostic factors in acute myeloid leukemia (AML)].
Zmorzyński S; Filip AA; Koczkodaj D; Michalak M
Postepy Hig Med Dosw (Online); 2011 Mar; 65():158-66. PubMed ID: 21502692
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
9. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
Imai Y
Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review.
Baldus CD; Mrózek K; Marcucci G; Bloomfield CD
Br J Haematol; 2007 Jun; 137(5):387-400. PubMed ID: 17488484
[TBL] [Abstract][Full Text] [Related]
11. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
[TBL] [Abstract][Full Text] [Related]
12. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
13. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
14. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
15. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
16. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia.
Hou HA; Lin CC; Chou WC; Liu CY; Chen CY; Tang JL; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Kuo YY; Lee MC; Liu MC; Liu CW; Lin LI; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Leukemia; 2014 Jan; 28(1):50-8. PubMed ID: 23929217
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
18. Acute Myeloid Leukemia: Diagnosis and Management Based on Current Molecular Genetics Approach.
Suguna E; Farhana R; Kanimozhi E; Kumar PS; Kumaramanickavel G; Kumar CS
Cardiovasc Hematol Disord Drug Targets; 2018; 18(3):199-207. PubMed ID: 29766829
[TBL] [Abstract][Full Text] [Related]
19. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
[TBL] [Abstract][Full Text] [Related]
20. [Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
Han TJ; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1063-8. PubMed ID: 20723330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]